Last checked at 25 Jun 2020 15:16
25 June 2020
Microsaic Systems plc
("Microsaic" or the "Company")
Result of AGM
Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting today were duly passed on a poll, the results of which are set out below:
| Ordinary resolutions | Votes for | % of votes cast | Votes against | % votes cast | Votes withheld |
1 | To approve the audited accounts of the Company for the year ended on 31 December 2019, together with the Directors' Report and Auditors' Report thereon | 329,369,671 | 100.00 | - | - | 500 |
2 | To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the remuneration of the auditors | 329,176,504 | 99.94 | 193,667 | 0.06 | - |
3 | To re-appoint Bevan Metcalf as a Director of the Company | 329,370,171 | 100.00 | - | - | - |
4 | To authorise the Directors to allot equity securities up to an aggregate nominal amount of £380,304 | 329,176,504 | 99.94 | 193,667 | 0.06 | - |
| Special resolution | Votes for | % of votes cast | Votes against | % votes cast | Votes withheld |
5 | To dis-apply statutory pre-emption rights | 328,461,504 | 99.73 | 908,667 | 0.27 | - |
Enquiries:
Microsaic Systems plc | +44 (0) 1483 751 577 |
Glenn Tracey, CEO |
|
Bevan Metcalf, FD
|
|
N+1 Singer (Nominated Adviser & Joint Broker) | +44 (0)20 7496 3000 |
Aubrey Powell / George Tzimas (Corporate Finance) |
|
Tom Salvesen (Corporate Broking)
|
|
WH Ireland Limited (Joint Broker) | +44 (0)20 7220 1666 |
James Joyce (Corporate Finance) |
|
Jasper Berry (Corporate Broking) |
|
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.
Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com.